Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer
Internal and external validation has demonstrated that the model is highly discriminative and stable and can be used to assess the risk of early recurrence in NMIBC patients and to guide clinical decision-making.
Authors
- Xinqi Yang (ORCID: https://orcid.org/0000-0002-2345-3307)
- Jiangrong Zhang
- Neng Zhang (ORCID: https://orcid.org/0000-0002-2063-1550)
- Rongrong Yang (ORCID: https://orcid.org/0009-0008-6125-1491)
- Jiajia Tang (ORCID: https://orcid.org/0000-0001-6036-6133)
- Yuanjian Liao
- L. Fan (ORCID: https://orcid.org/0009-0007-6680-5556)
- Tianyu Huang (ORCID: https://orcid.org/0000-0002-8373-2789)
- Mingshun Zuo
Institutions
- Zunyi Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1467527
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China